electroCore's New Playbook: Federal Penetration, Consumer Efficiency, and a Record Quarter
A Record Quarter
electroCore, Inc. (ECOR) reported first-quarter 2026 results on May 6, 2026, delivering a record quarter that validates its dual-pronged strategy of expanding within federal channels while sharpening consumer wellness economics. Revenue reached $9.6 million, up 43% year over year, and gross margin expanded to 87% – a 200 basis point improvement. This is the clearest signal yet that the company is executing on its plan, as CEO Josh Lev noted: “We just delivered our highest revenue quarter ever-$9.6 million, up 43% year over year.” — Joshua S. Lev, Chief Executive Officer · 2026-05-06
The New Leadership and Its Focus
The quarter was also notable for the leadership transition. Thomas Errico stepped in as interim chairman, Josh Lev became CEO (previously CFO), and Mike Fox joined as COO in April. Fox brings three decades of federal healthcare experience, and his mandate is clear: deepen the VA presence and expand into the broader Department of Defense ecosystem. He quickly articulated his priorities:
My major priority is the VA and Department of Defense markets. We have just scratched the surface of penetrating the addressable VA headache market.
Fox's background suggests a shift from broad facility coverage to deeper utilization within existing sites. He emphasized the 1099 sales model and the need for more prescribers per facility. This is a strategic evolution from the prior approach of expanding the number of hospitals, as Daniel Goldberger described earlier: “from the VA channel, we've had a lot of acceleration over the course of the last year in 2025. And we've been pretty adamant that we believe the way for us to go ahead and grow that is to increase the number of boots on the ground...” — Daniel Goldberger, CEO (implied as he is leading the call and referred to as architect and leader) · 2026-03-19 That same call also highlighted the long-awaited Kaiser contract: “we finally got on contract with Kaiser” — Daniel Goldberger, CEO (implied as he is leading the call and referred to as architect and leader) · 2026-03-19, which remains a key commercial beachhead.
Federal Expansion Beyond the VA
The company is not resting on its VA success. Fox highlighted the Department of Defense as an underdeveloped opportunity for both prescription products and the TAC STIM human-performance device. TACSTIM has been involved in research with Air Force Special Operations Command, Army Special Operations Command, and the Air Force Research Laboratory, and the heightened military tempo is driving demand. Fox expects incremental revenue in Q3 or Q4: “I would expect by sometime Q3, Q4, with our plan in place, that we will start seeing additional revenue.” — Mike Fox, Chief Commercial Officer · 2026-05-06
The VA opportunity remains large – management estimates roughly 15,000 veterans have received gammaCore, representing about 2.5% penetration of the addressable market. Quell fibromyalgia, acquired from NeuroMetrix in May 2025, surpassed $1 million in quarterly revenue for the first time, a sign the product is gaining traction within the same sales channel. In a prior call, Goldberger noted the faster-than-expected adoption: “the uptake has been much faster than we expected” — Daniel Goldberger, Chief Executive Officer · 2025-11-05.
Consumer Wellness: Efficiency Over Speed
On the direct-to-consumer side, TruVega revenue grew 38% to $1.5 million, but the company deliberately tempered top-line growth to improve unit economics. ROAS improved 14% sequentially to 2.37, driven by a shift toward affiliate and influencer partnerships. This efficiency gain is reflected in the gross margin expansion. "Our return on advertising spend, or ROAS, was approximately 2.37 in the period, a 14% improvement over the prior quarter," said Lev. The company is also preparing to relaunch Quell Relief over-the-counter later this year, and it has introduced TruVega in the UK.
Financial Position and Catalysts
The company reaffirmed its full-year 2026 revenue guidance of approximately 30% growth, translating to roughly $9-10 million of incremental revenue. The path to profitability is supported by strong gross margins and disciplined cost management. Total Revenue reached $10 million in the quarter, up 43% year-over-year. Operating income improved sequentially, and the company is managing cash carefully, with cash and marketable securities at $8.8 million at quarter end. The stock has responded strongly, up 73% over the last 90 days.
The clinical pipeline remains a core catalyst, particularly the PTSD Breakthrough Designation and ongoing studies with Acacia Clinics. A new publication in Frontiers in Neuroscience supports the platform's potential for mild traumatic brain injury and PTSD. The Vagus Nerve stimulation platform continues to generate evidence across multiple indications.
In summary, electroCore is executing on a clear plan: deepen federal penetration, build the consumer wellness business efficiently, and advance the clinical evidence base. The new leadership under Mike Fox adds a seasoned operator who knows how to scale within complex government channels. With record revenue and improving margins, the company appears to be turning the corner.